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Abstract
In early-stage drug discovery, thousands of compounds must be tested using in vitro
assays to determine their exposure and safety characteristics. This data is used to guide
the selection of potential drug candidates and to help chemists in optimize the properties
of those compounds. At Novartis, an internal service organization called Preclinical
Compound Profiling (PCP) provides these services to the company as a whole. The
purpose of this internship was to help PCP make significant improvements in cycle time
and cost effectiveness without reducing the quality of information provided to their
customers.
The project utilized a series of deterministic and stochastic models to predict the impact
of multiple operational changes on cost and cycle time. The data from each model was
synthesized to create a unified view allowing combinations of changes to be analyzed
together. This data was evaluated in the context of the customer needs and organizational
strategy to present recommendations. Changes were implemented that will reduce
materials spending by $500,000 per year while simultaneously increasing capacity,
reducing cycle time, and improving customer value. Additional recommendations were
developed that will enable further improvements.
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Introduction
1.1 The Pharmaceutical Industry
A major challenge facing the pharmaceutical industry is illustrated in Figure 1. It shows
that even with dramatically increasing R&D expenditures, the number of new drugs or
New Molecular Entities (NMEs) approved has remained relatively constant.
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Figure 1 - Pharmaceutical Industry Productivity1
Since it typically takes 10-15 years to develop a new drug 2, productivity may increase in
future years. However, today the industry faces significant pressure to contain rapidly
increasing research costs. The industry is also threatened by increased competition from
generic drug manufacturers. The value of drugs that will lose patent protection is forecast
to increase significantly in the next few years. In 2005, drugs worth $12 billion in sales
lost patent protection followed by $23 billion in 2006 and a forecast $16 billion in 2007.3
The overall pharmaceutical market is forecast to grow at a slower rate of only 4-5% in
2007, significantly slower than the average of 11% experienced between 1970 and 2005. 4
All of these factors contribute to reduced profitability in the industry as a whole. Figure 2
below shows the overall Return on Assets (ROA) of pharmaceutical companies over the
past thirty years. Since 2000, ROA has decreased significantly, creating further pressure
on industry executives to improve performance.
1 Source: Congressional Budget Office. Research and Development in the Pharmaceutical Industry. 2006
2Source: Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2006
3 Source: IMS Health. Changing Market Dynamics in 2007. December 18th 2006.
<http://pharmalicensing.com/features/disp/ 1166448792_458698987263a>
4Source: Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2006
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Figure 2 - Median Return for Pharmaceutical Companiess
Given this industry situation it is imperative for companies to increase their return on
their research and development investments. The purpose of this thesis is to analyze one
department at the Novartis Institutes for BioMedical Research, Preclinical Compound
Profiling (PCP), and to identify ways to improve their overall cost-effectiveness.
1.2 Novartis and NIBR
Novartis was created as the result of a merger between Ciba-Geigy and Sandoz in 1996.6
Both were headquartered in Switzerland and had been in business for more than 100
years. Novartis is the fourth largest pharmaceutical company by market share holding a
5% worldwide market share compared to industry leading Pfizer with a share of 8.7%. 7 In
2006, the company had sales of over $37 billion, net income of over $8 billion and
employed more than 100,000 people.8
In 2002, Novartis announced the creation of the Novartis Institutes for BioMedical
Research (NIBR). This new organization would function as the research arm of Novartis,
responsible for the discovery of new medicines. It was also announced that this new
organization would move the headquarters to Cambridge, Massachusetts from Basel
Switzerland.
Dan Vasella, CEO of Novartis, chose to locate in Cambridge to attract local talent, to be
close to leading universities and hospitals, and to have a greater presence in the world's
5 Source: Research and Development in the Pharmaceutical Industry. Congress of the United States
Congressional Budget Office. 2006
6 Source: Novartis A.G. Website, <http://www.novartis.com>.
7 Source: Global Pharmaceuticals Industry Profile. Datamonitor. December 2006
8 Source: Novartis A.G. Novartis Annual Report 2006.
<http://www.novartis.com/downloads/investors/reports/AR06_E_web.pdf>
largest pharmaceutical market.9 Since then Novartis has won awards in both 2005 and
2006 for having the best pipeline in the pharmaceutical business.' 0
1.3 Thesis Outline
This thesis is organized into the following nine chapters.
Chapter 2 provides background information on how Preclinical Compound Profiling
(PCP) fits into Novartis' overall drug development process. It also discusses the basic
requirements of a successful profiling organization
Chapter 3 discusses the profiling technology and investigates how well the organization
has performed on three key metrics: capacity, cycle time, and cost. Also provided is
additional information on the cost structure and products offered in Preclinical
Compound Profiling.
Chapter 4 presents a typical process flow diagram, showing each step that takes place
between the initiation of a customer order and order fulfillment. Based upon that process
flow, areas of opportunity will be identified that could significantly reduce the overall
cycle time.
Chapter 5 analyzes a proposal to more efficiently allocate capacity by allowing a flexible
assay ordering system for the Safety Pharmacology area in PCP. A model will be
presented showing the potential costs and benefits. Also discussed is an intermediate
proposal to gain some benefits of flexible ordering without the associated investment
costs.
Chapter 6 will discuss three proposed changes to the operations of the Safety
Pharmacology area: assay run frequency, assay location, and outsourcing. Several simple
models will be introduced to evaluate the impact of these changes on cost and cycle time.
Results from the models will be synthesized to provide a unified view of how the changes
interact and affect the key output parameters.
Chapter 7 investigates the long-term strategy of the PCP organization and provides
recommendations on strategies to maximize the long-term value of the group.
Chapter 8 describes the organizational structure of the PCP group and provides
recommendations on organizational changes.
Chapter 9 summarizes the recommendations presented in the thesis and general
principles that can be applied to similar situations.
9 Source: Naik, Gautim. Vasella Drives Stodgy Novartis into a New Era. Wall Street Journal. B1. 13
October 2003.
1o Source: SCRIP Awards Website. 2006. <http://www.plibubs.com/scripawards/index.htm>
2 The role of Profiling in Drug Discovery
2.1 The Drug Discovery Process at Novartis
The drug discovery process at Novartis is described in Figure 3.
Figure 3 - Novartis Drug Discovery Process n
The process begins with the discovery of the mechanism and pathway of a disease.
Researchers identify a specific interaction in the pathway that could be blocked by an
antagonist or stimulated by an agonist and then validate the target to ensure that
modulating the target causes a measurable response. Once a target is identified and
validated, Novartis scientists move on to the next stage where they develop assays that
can be used to test potential compounds with broad chemical diversity to see if they will
have affinity to the target. When an assay is successfully developed, the program moves
to the Hit Discovery stage and performs High-Throughput Screening (HTS). In a typical
screen, about a million compounds from the Novartis compound archive are tested to
determine if they will successfully bind to the target. Compounds that bind to the target
are called "hits." These hits are evaluated in more detailed screens to determine their
potency. Additional tests are developed to validate that these hits actually bind to the
desired target rather than degrading the proteins used in the screening assay or binding to
multiple sites in addition to the desired receptor.
Once the hits are validated the program moves to the next phase called Hit-to-Lead
Finding. The objective of this phase is to further reduce the number of validated chemical
structures to those that have good potency, structure-activity-relationship (SAR) at the
therapeutic target and reasonable exposure and safety parameters. This stage ends with
Lead Nomination. During the following stage, Lead Optimization, lead compounds are
modified by medicinal chemists in order to optimize their structure to obtain maximum
potency, exposure and safety. Chemists in this phase rely on a variety of in vitro and
animal studies to gain insights into how their structural changes to the compound affect
its properties in a living system.
Promising compounds progress to the Candidate Selection Process (CSP) where they are
prepared for a Proof of Concept (PoC) trial. This is a human trial of the drug in a small
population that may have the disease of interest or a different disease with a related
mechanism. The purpose of the PoC is to validate that the drug has a measurable
therapeutic efficacy in humans without major safety problems. Doing a PoC very early in
the clinical development is designed to increase the likelihood of success before
beginning very expensive and lengthy clinical trials.
1 Source: The Novartis Institutes for BioMedical Research Website, <http://nibr.novartis.com>.
If the compound is successful in the PoC, it moves into full clinical development and a
series of human trials. If the compound appears to have acceptable an efficacy and safety
profile, it is submitted for final approval to the Food and Drug Administration (FDA).
2.2 Preclinical Profiling
2.2.1 The Purpose of Preclinical Profiling
The mission of Preclinical Profiling (PCP) is to "support the needs of drug
discovery projects by providing essential information on compound properties to help
lead selection and lead optimization."l2 They accomplish this by analyzing the exposure
and toxicity properties and liabilities of compounds with in vitro assays. Exposure is the
ability of the drug to reach a significant concentration in the body and is also referred to
as bioavailability. Toxicity is the ability of the drug to cause damage or unacceptable,
undesirable side-effects. The path that oral drugs take through the body is shown in
Figure 4 below.
To faeces Metabolism Metabolism
Figure 4 - Pathway to Bioavailability'3
Orally administered drugs must pass several hurdles before they can become effective in
the body. The first obstacle is absorption. Absorption is primarily dependent on two
factors: solubility and permeability. To enter the bloodstream the drug must be soluble in
the gut environment and must be capable of passing through the cell membrane of the
intestinal wall. Some drugs can compensate for low solubility with high permeability and
vice-versa, but drugs with low solubility and low permeability are rarely successful. 14
12 Novartis Internal Website: http://nibr.novartis.intra/DT/ldc/pcp/index.jsp
Suzanne Tilton. Novartis Internal Presentation. Physicochemical: Pka and Log P/D. May 11 2006
14 Source: Lipinski, C.A. et al. Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. 1997
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Once the drug has made it into the cells of the body it faces the second obstacle:
metabolism. Blood flows from the intestines to the liver, the primary organ responsible
for drug metabolism. In the liver, many different enzymes can act upon drugs to change
their functional groups and potentially render them inactive or alternatively unsafe in the
body. Drugs that are rapidly metabolized are unlikely to be effective because they will
never reach a significant concentration in the body in the form in which they were
delivered.15
The problem of toxicity is the third major obstacle drugs face in becoming effective in a
living person. When a drug is present at the required concentration in the bloodstream, it
can cause the desired, therapeutic effect or it can cause an undesired, off-target effect.
These effects can range from a mild case of nausea to heart failure and death. Almost any
drug becomes toxic at high concentrations. The difference between the concentration
required to create the therapeutic effect and the concentration required to create a toxic
effect is called the therapeutic index. Medicinal chemists always try to maximize the
specificity and potency of their drugs at the desired target to make the therapeutic index
as large as possible.
2.2.2 Requirements for Successful Preclinical Compound Profiling
Profiling data is primarily used in the Hit to Lead Finding and Lead Optimization stages
of drug discovery. In Lead Optimization the process is iterative. Chemists synthesize a
compound or group of compounds and then need to test the compound's properties. At
each cycle they evaluate the effect of each change to the compound's structure and then
devise new modifications to test. At the end of the process they hope to optimize three
parameters simultaneously: efficacy, exposure and safety. To support this activity, PCP
needs to provide assays that are fast, inexpensive, and predictive.
It is critical that profiling data is provided to chemists quickly so that they can make the
best decision on what to do in their next synthetic cycle. If a chemist is missing some
useful data she will most likely go ahead and move to the next synthetic cycle based on
the information at hand. With incomplete information it is less likely that the chemist will
make the best decision. This causes delays, frustration, wasted effort and worst,
uneducated decisions. For this reason it is critical that PCP provide data quickly to
support chemists in making the best decisions possible.
Chemists in early-stage drug discovery at Novartis produce tens of thousands of new
compounds each year in their attempts to create a few promising new drugs. Because the
number of compounds is so large it is vital that inexpensive means are employed to
measure their properties. PCP needs to operate a high-volume, low cost set of assays to
support these requirements.
15 Source: Pritchard, J.F., et al. Making Better Drugs: Decision Gates in Non-Clinical Drug Development.
2003.
The data that PCP generates is used to make key decisions about the direction of drug
discovery programs and is often an important factor in the decision to discontinue
development of compound scaffolds. The type of assays that PCP chooses to offer must
be well correlated with actual effects in living systems. Otherwise the results will be
misleading and will lead to poor decisions.
Interestingly, profiling data does not need to be extremely precise or extremely
accurate. At this early stage of development it is very important to be able to say that a
compound will have high solubility rather than low solubility, but exactly how high or
how low isn't as critical until later in the process. It is preferable to have an assay that is
always in the correct order of magnitude, than it is to have an assay that is usually within
5% of the true value but 20% of the time it is completely wrong.17
3 Profiling Technology and Performance Overview
This section will describe the basic principles involved in performing an assay and the
technology employed. It will also describe the basic assays that are performed by the
preclinical profiling group with specific focus on the safety pharmacology assays. The
cost structure and recent performance of the PCP organization will also be discussed.
3.1 Profiling Technology
Preclinical compound profiling must process thousands of compounds every year that are
generated in Novartis' labs. Each compound is only available in low milligram quantities,
and the cost of specialized proteins, radioligands, and other reagents can be hundreds of
dollars per milligram. In this environment it is critical to have technology that will allow
the scientists to obtain high quality data on many different compounds using tiny
amounts of compounds and reagents. This section will describe the basic technology used
to perform the assays.
In Preclinical Compound Profiling, compounds arrive in the form of microtubes that
contain up to 500iL of a standard 10mM solution of the compound in the solvent DMSO
(dimethylsulfoxide). Up to 96 tubes, each containing one compound in solution are
arranged together on racks such as the one shown below.
16 Uusitalo, Jouko. ADME Solutions from Drug Discovery to Lead Optimisation, Candidate Selection and
Beyond. 2005.
17 Based on interviews conducted by the author with multiple NIBR scientists.
Figure 5 - 96 Tube Rack18 & 384 well Plate
Automated liquid handling systems, such as the one shown below in Figure 6, can
accurately transfer very small amounts (10-100tL) of the samples into 96 or 384-well
plates (shown in Figure 6 above) for further processing. Each sample is serially diluted to
create a series of wells with progressively decreasing concentrations of the compound to
be studied. Typical concentration curves go from 30jM to 3 nM.
.& xl .M %, V - . JU U,, M-ALtjUALA &•.K"L KAXl
The automated liquid handlers are often integrated into a bench scale system that can
perform an entire experiment on multiple assay plates. The operator must first setup the
equipment and supply all of the necessary reagents and sample plates. Once the setup is
18 Microtube Rack System. Samin Science Company Website
<http://www.saminsci.com/html/business/general vails03.htm>
19 BioTek Company Website. BioTek Precision 2000 Automated Pipetting System.
<http://www.biotek.com/products/tech res_detail.php?id= 114>
complete the system follows a program selected by the operator that performs all of the
steps in the assay protocol. Some systems integrate the appropriate reader to perform
experimental data collection, while others require separate data acquisition equipment.
3.2 Assays Offered
To provide the information that chemists need in drug development PCP offers a broad
selection of major assays. These assays are described in the table below.
Assay Name Data provided
PAMPA Permeability
HT-Sol Solubility
HT pKa Ionization Constant
Microsomal Stability Metabolism
CYP 450 IC50 Inhibition of Metabolism (Drug-Drug Interactions)
Caco - 2 Permeability & Efflux
HERG binding Cardiac Q-T Prolongation
Safety Pharmacology Panel Side-effects (adverse drug reactions)
Micronucleus Genotoxicity
Hepatotox Liver Toxicity
Table 1 - Profiling Assays Performed at Novartis
The Preclinical Compound Profiling department publishes a catalog that contains a list of
all available assays, the committed turnaround time for each assay, and an estimate of the
cost of each assay. Since individual departments are not billed for the assays they request,
this data is provided to help the requestors make reasonable decisions about how many
compounds to submit to a single assay.
3.2.1 Scintillation Proximity Assays
This thesis will focus on the Safety Pharmacology area within PCP. Safety Pharmacology
uses two primary types of assays: filtration binding assays and scintillation proximity
assays (SPA). The SPA format will be described in detail as it is the dominant format
employed at Novartis.
Any safety pharmacology assay begins with an identified and purified biological
receptor. These are typically protein structures in the body that are known to cause a
specific biological response when a ligand that matches the receptor site interacts with
the receptor. Drugs often function by inserting themselves into the receptor and
preventing the ligand from binding to the receptor and sending the signal which causes
the biological response. This behavior is shown in Figure 7 below.
,I
W I Ila l E IIEILLU SSignalTra smitted
Signal
Blocked
Figure 7 - Receptor Binding Diagram20
In a scintillation proximity assay, radioactive isotopes are attached to the ligands, and
scintillation beads are attached to the receptors. The scintillation beads are made from
either yttrium silicate or PVT (polyvinyl-toluene). Both compounds emit light in the
visible spectrum when exposed to low-energy radiation.
If a radioligand successfully binds to the receptor, the radioactive tag will cause the bead
to fluoresce, creating a measurable light emission. This is shown in Figure 8 below. The
radioactive isotopes used are typically 3H and 1251 because both emit low energy beta
particles that can only travel about 10um in water.
A
Figure 8 - Scintillation Proximity Assay Diagram "On" State2 1
Ligands that are not bound to a receptor will not be close enough to the scintillation bead
to produce a response. This behavior is shown in Figure 9 below. In this case the
radiation is absorbed by the water in the solution and will not cause the bead to emit light.
20 Alex Fekete. Novartis Internal Presentation. In vitro Safety Pharmacology. May 2006.
21 Fekete, Alex. Novartis Internal Presentation. In vitro Safety Pharmacology. May 2006.
MF
Figure 9 - Scintillation Proximity Assay Diagram "Off" State22
Scintillation detectors are used to measure the relative amount of light emission and
determine to what extent the drug bound to the receptor and blocked the ligand from
binding. These detectors will record a value for the intensity of light emission for each
well on the microplate. If the drug is very effective at binding to the receptor, then at high
concentrations of drug we would expect the light emission to be close to zero. Reference
wells without the drug being tested are used to establish the maximum intensity, while
other reference wells are populated with a known drug that binds to the receptor
establishing the low reference point.
Once all of the data is collected, the data points are fit to a curve in order to determine the
IC50, or the concentration at which the compound inhibits 50% of the normal binding of
the radioligand. A typical example of a compound that bound to the ligand is shown in
Figure 10 below.
Compound A
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Figure 10 - ICso Determination
In any given assay, most compounds are inactive and show no significant change in
binding even at concentrations up to 30uM. This behavior is shown in Figure 11 below.
In this case the profiling group reports the IC50 as being greater than 30uM.
22 Fekete, Alex. May 2006
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Figure 11 - Inactive Compound
PCP collects this data for each assay and each compound and uploads it to a central
database that stores all compound-related information.
3.3 Cost Structure
The largest source of cost in the Cambridge profiling organization is personnel. Entry
level associates all have Bachelors or Masters degrees in science and nearly all lab heads
or supervisors have Doctorate degrees. The distribution of costs is shown in the figure
below.
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Figure 12 - PCP Expenses by Category
This breakdown allows us to see where the opportunities lie in reducing the cost of the
assays on a per-compound basis. Personnel, capital, and overhead are relatively difficult
to modify in the current business environment. Also, PCP output is capacity constrained
rather than demand constrained for most assays. This leads to the conclusion that the best
opportunity for reducing costs per compound is through increasing capacity and
utilization of the current resources.
Materials costs are also a significant cost component and are much easier to change
through improvement projects. However, these costs are not split evenly between the
various types of assays. The Safety Pharmacology group consumes about forty percent of
the total budget and about two-thirds of the materials budget, meaning that some of the
best opportunities for savings are in the Safety Pharmacology area. As a result, much of
this thesis will focus on potential improvements to the Safety Pharmacology department.
3.4 Performance
The performance of the PCP group is challenged by average demand that is above their
stated capacity. They also face high demand variability. Figure 13 below shows a typical
demand pattern and capacity level for two assays, Safety Pharmacology and Caco-2
which both experience very heavy demand.
Figure 13 - Weekly Demand Patterns vs. Capacity
Table 2 shows the five major assay groups, the coefficient of variation of demand, and
the overall capacity utilization.
Assay Group CV Utilization
Solubility & Permeability 0.5 85%
Metabolic Stability 0.5 110%
Caco-2 0.3 150%
hERG channel 0.3 115%
Safety Pharmacology 0.4 158%
Table 2 - Assay Demand Variability and Utilization
Based on this information we can see that variability is significant and that in many cases
utilization exceeds 100%. Given this information we would expect nearly infinite queues
--- Caco-2
-m-- Pharmacology
-- Caco-2 Capacity
-- Pharmacology Capacity
Week
I I IV It-
V X/
for some of these assays. Although several assays experience long queue times, none
have showed continuous build-up due to the fact that capacity is somewhat fungible in
PCP.
3.4.1 What is Capacity?
As mentioned previously, labor is the most significant component of cost in PCP.
Interestingly, it also turns out that labor is the primary system constraint. Equipment is
often idle and there are always compounds available for testing. Classic views on dealing
with constraints would tell us to subordinate everything in the system to the constraint to
maximize the system performance.23 However, performing the assays is only one piece of
the job description of a typical associate working in PCP. They are also responsible for
assay improvement projects, new assay development, supporting project teams and many
other tasks. The amount of time that they can dedicate to performing the assay is not
necessarily fixed from week to week.
Given that the associates' time is the constraint, it is useful to investigate how the
capacity is determined. At Novartis the PCP organization publishes a catalog that lists
each assay they perform, how many compounds they can process each year, the
turnaround time or cycle time for each assay, and how much each assay costs the
company on a per-compound basis. The capacities stated in this catalog are typically
determined based on an assay schedule chosen by the profiling department. For example,
the pharmacology area prefers to run their assay once every two weeks. If their
equipment was setup to handle 4 plates per assay and each plate held 10 compounds, they
would state their yearly capacity as 1000 compounds (40 compounds per run with 25 runs
per year).
In reality, the pharmacology area could process many more compounds than their stated
capacity by either increasing the number of compounds per run or by running the assay
more frequently. When they increase the time spent on performing the assay they will
naturally be forced to spend less time on their other job responsibilities. As is often the
case with knowledge workers, it is extremely difficult to precisely determine how much
time various projects should take and to quantify how busy or how well utilized a
particular worker is. This in turn makes it extremely difficult to determine what the true
underlying capacity is.
In the Safety Pharmacology area, the associates have been inserting extra assay runs into
their schedule whenever the queue becomes very long. Similar strategies are used by the
associates in other areas, explaining how they are able to operate at a utilization of over
100%.
3.4.2 Cycle Time
Before discussing cycle time performance, it is important to understand how cycle time
was defined in PCP. For most assays, cycle time began when an associate picked up a
23 Source: Goldratt, Eliyahu. The Goal: A Process of Ongoing Improvement. 1984
compound for analysis and ended when data was uploaded to the database. Based on this
criteria, most of the profiling assays met their cycle time goals because the process of
performing the assay was consistent and had a relatively stable cycle time.
The critical problem with this metric was that the measured and reported cycle time did
not correspond to the cycle time experienced by PCP customers. The metric did not
measure the entire process, it only measured the small piece that occurs within PCP. The
metric ignored the process of getting compounds to the profiling lab as well as the queue
time that compounds experienced waiting for profiling to retrieve them. This process will
be discussed in detail in section four.
When we include only queue time before PCP along with process time in PCP, the cycle
time picture is not good. Figure 14 below shows the week by week cycle time
performance of two selected assays, Safety Pharmacology and hERG.
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Figure 14 - Cycle Time vs. Goal
As you can see from the chart above, Safety Pharmacology rarely achieved its cycle time
goals. The hERG assay performed better but still frequently exceeded its cycle time goals
as well. These two assays along with a few others have persistent problems meeting their
cycle-time requirements when the length of the entire process flow is considered.
3.4.3 Cost
On a per-compound basis, preclinical profiling is typically cost-competitive versus
external vendors, with a few specific exceptions. Table 2 below shows the external cost
of several assays compared to the calculated internal costs.
0,
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0
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A 1
External
Assay Cost
A 281%
B 65%
C 187%
D 70%
E 99%
F 240%
G 204%
Table 3 - External Cost as a Percentage of Internal Cost24
These comparisons were made versus third party vendors that typically perform assays on
small numbers of compounds for many different customers. It is reasonable to expect that
an internal organization with a stable flow of compounds going to a small, fixed
collection of assay formats would be able to outperform these types of vendors. Another
interesting comparison is how PCP compares with other profiling organizations that are
captive within large pharmaceutical companies. Based on an internal study, NIBR
estimated the labor per compound tested for major competitors. This measure is not as
complete as total cost, but since labor is a large fraction of overall costs it is a reasonable
surrogate. The results for several assay technologies is shown below in Figure 15.
Figure 15 - PCP Productivity Benchmarking25
24 Based on 2006 historical costs and outsourcing quotes from multiple vendors compiled by Melanie Hann25 Data from NIBR analysis performed by Jianling Wang.
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Based on this data the NIBR Profiling group has costs that are significantly below
industry average. However, in several assay technologies there is room to improve to
match best-in-class performance.
Overall, we can conclude that costs on a per compound basis are not unusual with respect
to third party vendors and other pharmaceutical companies. However, these per
compound costs for existing assays exclude portions of the overall profiling budget. PCP
spends a significant portion of its resources on new assay development. In 2006 this
fraction was near 30%. PCP also performs a significant number of secondary assays that
account for about 10% of its budget. These are typically more labor intensive, more
expensive, and done in very low volumes. Since spending on development activities and
secondary assays is not included in the cost per compound calculations for the primary
assays shown above, the overall profiling budget is significantly larger than one would
estimate based on the primary assays alone. This contributes to the perception by some in
the company that PCP is relatively expensive.
4 Process Flow Analysis
4.1 Profiling Process Flow Description
The process of obtaining profiling data on a potential new drug begins and ends with a
medicinal chemist. The chemist will synthesize a new compound and decide to submit
that compound for testing. To do this they must first fill out an electronic request in the
Test Request Tool (TRT). This is the first step in the process flow diagram shown below.
The diagram is color coded showing the currently accepted areas of responsibility for
each section of the process flow. Green corresponds to the requesting chemist, orange to
the Compound Management Unit (CMU), and blue to Preclinical Profiling. The average
duration of each process step in the case of the Safety Pharmacology assay panel is also
indicated in units of business days.
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Figure 16 - PCP Process Flow Diagram
After submitting the electronic request they must physically deliver the compound and its
associated documentation to the Compound Management Unit (CMU). This is done by
physically walking to the location or by interoffice mail depending on the location of the
chemist. Once the compound is dropped off at CMU it goes into a queue for processing.
Compounds are typically processed the day after they arrive. CMU will register the dry
compound and create a 10mM standard solution in DMSO (dimethylsulfoxide). They will
then take aliquots from this standard solution to create individual samples for each assay
package that was requested by the chemist. These samples are then delivered to a cold
storage area where they wait to be retrieved by PCP associates.
The PCP associates will retrieve the samples from the cold storage area just prior to
beginning their assay. They will use the solutions to create an assay plate in the
configuration required by their assay. They will then process the assay plates on their
automated equipment. The data collection process for each assay varies. Some assays
require the use of mass spectrometer equipment that resides in the Central Technologies
(CT) department. For these assays the samples must be delivered to CT who then send
the data when the measurements are complete. For the remaining assays the detection
equipment is present in PCP.
Once the necessary data is collected the associates must retrieve and analyze the data.
Typically this is accomplished in Excel templates. They check the data quality to ensure
the assays were performed properly. Occasionally the data will indicate problems with
the assay and the assay has to be repeated.
I
When the data analysis is complete the data must be properly formatted and uploaded to
the centralized compound data repository. Once the data is uploaded chemists can view
the data using a variety of programs and queries. Currently, there is no automatic
notification system to inform chemists when new data is available. Because of this, the
profiling department typically summarizes the data from all compounds in a batch and
sends out an email to all of the requestors informing them of the results.
4.2 Process Flow Cycle Time Analysis
To gain some insight into how long each process step takes I chose to examine just one
assay, the Safety Pharmacology assay, which typically has the worst cycle time
performance. Figure 16 above shows the average cycle times for each step in performing
the Safety Pharmacology assay.
Looking at the Process Flow Diagram we can see that there are several opportunities to
improve cycle time. The first in is the assay queue. The length of this queue is primarily
dependent upon the schedule chosen for the assay itself. In the case of the Safety
Pharmacology assay, the biweekly schedule forces an average queue time of 5.5 business
days with a maximum queue time of 10 days. If the assay could be performed more often,
e.g. once per week, this queue time would be reduced from 5.5 days to 3 days.
The second opportunity is the process time of the assay itself. The physical process of
performing the assay, analyzing the data, and uploading the data can be done in 5 days,
however since the assay is only performed every two weeks, the data is frequently not
reported until the end of the 10-day cycle. Each day saved in the assay process time
results in the same savings in the overall process length.
A third opportunity exists in the shipping queue and shipping time. Since shipments are
made only once per week, the average queue time is 3 days with a maximum of 5 days. If
shipments could be eliminated or made more frequently we could realize significant time
savings.
These three opportunities will be analyzed in the context of specific change proposals
discussed in section 6.
5 Evaluating the Benefits of Flexibility
5.1 Why Individual Assay Ordering?
The 80-assay Safety Pharmacology Panel is used for three different purposes: defining
the promiscuity of a compound (the extent to which it is likely to cause diverse side
effects in the body), defining the therapeutic index (the difference between the dose
needed for a therapeutic effect and the dose that will cause significant off-target effects),
and defining the relationship between the chemical structure and specific off-target
activity. This is also referred to as the structure-activity relationship or SAR.
The structure of the panel, a single package in which all assays are performed together, is
well suited to defining the promiscuity of a compound. However, since so many assays
must be performed it is expensive to process any single compound. This restricts the
number of compounds that can be run in a given year so that each program may only
submit a few compounds for testing in the Safety Pharmacology panel. This serves the
needs of development programs that are only interested in determining promiscuity,
however, this limitation makes it extremely difficult to develop structure-activity
relationships for individual targets (SARs).
Some programs are working on compounds that do not have promiscuity problems, but
have a specific and strong off-target effect that they would like to eliminate. In this case it
would be helpful to process many compounds with different structural modifications
through a single assay or a small group of assays. In this way they could determine the
SAR, or portion of the chemical structure is responsible for the off-target activity in a
specific assay.
To serve these types of customers, the profiling group developed the concept of
Individual Assay Ordering so that a customer could either order the standard panel or
order a customized a panel of assays to serve their specific needs. This system would give
the customers complete flexibility to order whatever is most appropriate for their specific
program and compounds.
The individual ordering structure also has the potential to enhance the allocation of
pharmacology resources. Customers would be able to use their expertise to select the
assays that provide the most useful and relevant information, rather than being forced into
a strict panel. More compounds could be processed in fewer assays, providing more
useful information for the same cost.
5.2 Costs and Challenges
The current system is not capable of allocating different compounds to different assays
within the panel. Today, all of the compounds requested for Safety Pharmacology
profiling are arranged in dilution curves on a set of 384-well master plates at relatively
high concentration. These master plates are copied directly by taking a tiny amount of
liquid from each well of the master plate, placing it into the matching well on the
daughter plate, and diluting it to the appropriate concentration. This procedure is
performed by an automated liquid handler with a 384-tip head that can transfer material
from every well on the plate in a single motion. In this process an identical set of plates
can be created for each of the assays in the Safety Pharmacology panel. However, there is
no clear way to produce different arrangements of compounds on the daughter plates.
In an individual ordering scenario it is possible that each assay will require a unique
combination of compounds and that each set of plates for each assay will be unique.
Managing this process by hand is not feasible, so an automated system must be created to
manage the process.
The automated system would need to gather data from the order database and inventory
database in order to match the right compounds with the right customer orders. Once it
understood which compounds would be required in which assays it would need to create
the appropriate assay plates for each of the assays.
This type of system would require new liquid handling hardware as well as software to
automate the complex compound-to-assay matching. It would also have to interface with
the data analysis system to ensure that the data from each plate could be matched with the
proper compound and assay protocol. After discussions with vendors in the industry we
determined that such system could be created using currently available products. Some
amount of software customization would be required, but nothing that is unusual with
respect to existing compound and assay managements systems in the industry.
5.3 Modeling the Impact of Individual Ordering
The aim of the modeling exercise was to determine how individual ordering would affect
the overall cost of running the P5 panel. Since compounds are processed in batches on
sample plates, the labor and materials required to perform the assay are primarily
dependent on the number of plates required rather than on the number of compounds
directly. For example, if an assay uses a plate format with a capacity of 16 compounds
per plate and we have 48 compounds to process, then we must use 3 plates and each plate
will be completely full. If we only have 33 compounds we still need to use 3 plates, but
the third plate will only have one compound present.
Historical Demand for the P5 Package shows a pattern of high variability with a
coefficient of variation of 0.4. Given this scenario we chose to model the impact of
Individual Ordering with a Monte-Carlo simulation. A Monte-Carlo simulation will allow
us to gain an understanding of the distribution of possible outcomes and make an
objective analysis based on more than assumptions about the average case.26
The model required an assumption regarding how to distribute orders for individual
assays among the entire assay panel. After interviews with customers and discussions
with senior individuals in PCP we chose to assume that orders for individual assays
would create an exponential distribution among the assay set. In any given week we
predicted that a few assays would be popular and requested often, a few more would have
a moderate level of requests, and that most assays would not receive any orders at all.
The reason behind this is that most programs submit compounds in groups. If a particular
program wanted individual ordering they would most likely submit a large number of
compounds for the same assay or group of assays. With several programs doing this each
week and with certain assays being much more common problems than others we
predicted that orders would be distributed among the assays in a pattern similar to the one
shown below.
26 Source: Ragsdale, Cliff. Spreadsheet Modling and Decision Analysis. 2004
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Figure 17 - Assumed Distribution of Orders by Assay
This chart above was created using the following expression:
1 a•i
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Where "i" is the index number of the assay, Wi is the relative weight for assay i, and "a"
and "P" are scale parameters to allow us to adjust the shape of the curve. Based on
interviews with customers and safety pharmacology experts we chose values for a and P
as 0.25 and 1 respectively. This provides for a relatively steep slope and a starting point
of about 0.8, consistent with our assumption that a small number of assays will be
ordered and that there will be significant overlap in the assays ordered by each customer.
Given this assumption the number of plates required for a specific assay "i" can be
expressed as the following:
Plates= W D -flnd + D (1- ffnd)
CPi
Where
Wi = Assay Weight for assay "i"
D = Demand in number of compounds
find = Fraction of orders for individual assays
Cp, = Compounds per plate for assay "i" from lookup table
The total number of plates needed for a complete run could then be found as :
_ _
For i= 1...n where n = number of assays
nW,.D. f D ++D- (1 - fInd)Total Plates= WId (i=l C i
In the Monte-Carlo simulation, a normal distribution was used for the parameter "D"
based on the mean and standard deviation of historical data. We also had to assume an
Individual Order Fraction (find), the fraction of total orders that were for individual assays
or small groups of assays as opposed to the entire panel. A single simulation creates
results like those in the figure below, showing the distribution of total plates required
under a single set of assumptions for demand (D) and Individual Order Fraction (fid).
Figure 18 - Monte-Carlo Simulation of Plates Required per run
While the simulation is running we also collect data on how many plates would have
been required if individual ordering was not enabled. Combining this information with
the materials cost of running one plate allows us to calculate the total savings due to
individual ordering in any specific run. An example of the simulation output is shown
below in Figure 19.
Figure 19 - Savings per Run When Using Individual Ordering
Once again we notice the discrete nature of the results. We can also see that in this set of
assumptions there is a high probability of moderate savings of $1000-$3000 per run and
then a moderate probability of a high savings of $6000-$10,000 per run. Since we know
the distribution of savings likely in any one cycle and that there are 26 runs in a given
year we can then determine the distribution of the likely savings that will accrue in any
single year as shown below.
Figure 20 - Distribution of Yearly Savings
5.3.1 Sensitivity Analysis
These examples only show the expected distribution under a single set of assumptions for
overall demand and for the individual order fraction. Since both of these parameters are
uncertain, we need to perform a sensitivity analysis to show how the results change as
both of these parameters vary. We performed an array of Monte Carlo simulations using
different assumptions for demand and for individual order fraction and then calculated
the average weekly cost. The results are shown in the figure below with the actual figures
disguised.
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Figure 21 - Sensitivity Analysis of Demand and Individual Order Fraction
The lines on the contour plot are iso-cost curves that show different options for utilizing
individual ordering. We could enable individual ordering while holding the capacity
steady, allowing for cost savings. Alternatively we could hold cost steady and climb up
the iso-cost curve, allowing us to run many more compounds at the same price.
5.3.2 Key Assumptions
All Compounds Processed Each Cycle
The model assumes that all compounds requested in a given cycle will be processed. No
compounds will wait and carry over to the next cycle. This assumption is valid so long as
the Safety Pharmacology area holds to their cycle time commitments. Past performance
shows that this is not always the case, however, recent improvements have increased run
capacity such that this assumption is likely to hold. There is the potential that deliberately
delaying some compounds could increase plate utilization and reduce costs. However,
since speed is so critical in drug discovery, the cost savings due to waiting and filling up
plates is unlikely to offset the cost of the delay.
b
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Exponential Demand for Individual Assays
Our assumption of exponentially distributed assay demand is based on customer
interviews. Most indicated that if they were submitting a compound for individual
ordering that they would request between 1 and 5 assays for that compound. Though we
cannot verify this assumption with actual data it is highly unlikely that the distribution
will be dramatically different. A distribution that is slightly more likely is still
exponential in its overall shape, but instead with large stair-steps that reflect the fact that
most orders will arrive in bundles, a few compounds for assay A & B, a few more for
Assays B&C, etc. However, our exponential distribution is a good approximation for this
type of stair-step pattern.
Normally Distributed, Constant Demand
The analysis also assumes that demand will remain constant throughout the year and that
it will be normally distributed. Figure 22 below shows that the assumption of normally
distributed demand is not grossly inaccurate. However, a log normal distribution may be
a little closer to the underlying historical data.
7
6-
5
- 4
0•
2-
1-
0- I
Compounds Ordered
Figure 22 - Histogram of Weekly Demand
The assumption of constant demand is less likely to be true over the long term. Demand
for Safety Pharmacology has been increasing along with continued expansion in NIBR's
research efforts. However, the sensitivity chart shows how the results will change as
demand changes.
5.3.3 Results
Our results showed that for the most likely scenario we could save less than $200,000 per
year in materials costs through individual ordering, and the 95% confidence interval was
between $160,000 and $240,000. Alternatively we could keep costs steady and increase
capacity by about 50%. We estimated the total capital cost of installing the system at $2
million based on discussions with vendors. Given the high investment required and the
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relatively modest savings, individual ordering will not pay for itself based on cost savings
in Safety Pharmacology alone.
As this analysis was ongoing it became evident that there are other areas within Novartis
that could benefit from the hardware and software necessary to do individual ordering.
Quantifying the benefit to these outside departments was determined to be outside of the
scope of this project, but it is still being evaluated by the compound management group at
NIBR.
5.4 An Alternative to Individual Ordering
Due to the high capital cost of installing an individual ordering system, other alternatives
were explored to determine if a lower cost option could capture some of the benefits. The
most common use of the Safety Pharmacology Panel is to screen for compound
promiscuity, i.e. how likely it is to affect other targets in the body besides the primary
target. One could probably accomplish this goal without using the entire panel of 80
assays. One proposal was to split the panel in two parts, running a reduced panel for most
compounds and only running the entire panel at selected decision points in the drug
discovery process. This scenario does not require significant additional investment and it
only requires a small amount of additional labor to perform. Also, if we could reduce the
size of the primary panel by 50% we estimated we could save approximately $500,000
per year in materials costs. The primary question then becomes which assays to place in
which panel.
Three important characteristics of the panel aid in this analysis: assay hit rate, assay to
assay correlation, and assay to side-effect correlation.
5.4.1 Assay Hit Rate
Based on historical data, certain assays are much more likely to show activity than others.
Currently, all compounds are screened in all assays at the same frequency. A more cost-
effective solution would be to screen compounds in the higher hit-rate assays more
frequently and check the lower hit-rate assays on a less frequent basis. Figure 23 below
shows the relative hit rate of many of the assays in the Safety Pharmacology panel.
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Figure 23 - Pharmacology Assay Hit Rate Pareto
Based on this information we can see that there are a significant number of assays with
very low hit rates. If we assume that future compounds will have a similar safety profile
as past compounds, it becomes relatively easy to identify some assays that could be
performed less frequently.
5.4.2 Assay to Assay Correlation
The Safety Pharmacology panel contains multiple assays from a single receptor family.
For example, there are three primary types of histamine receptors and each receptor has
its own assay. Each receptor is responsible for regulating different types of biological
responses including heart rate, bronchoconstriction, and gastric acid secretion.27
However, each receptor has a similar chemical structure so compounds that bind to one
of the receptors are likely to bind to the others.
Andreas Bender and Jeremy Jenkins at Novartis have used historical data on many
pharmacology targets to produce a matrix which shows how well correlated various
receptors are to one another (See Figure 24 below). Unsurprisingly, families of receptors
are often well correlated and show up as blocks of red along the diagonal. However, there
are many off-diagonal correlations as well, meaning that there are significant correlations
between different families.
27 Source: Foye, W.O. Principles of Medicinal Chemistry. 1995.
Figure 24 - Correlation Matrix of Safety Pharmacology Receptors28
The optimum panel would have a low inter-assay correlation to maximize the likelihood
of identifying potential problems.
5.4.3 Assay to Side Effect Correlation
Another important dimension to consider is the predictive capability of an assay and the
seriousness of the associated side effect. If a drug tests positive in one of the assays, the
probability of that drug causing a side effect when given to a real person is not known.
However, continuing research provides some insights into the predictive ability of these
preclinical assays. An optimized panel would include only assays that have significant
correlation to side effects in real people.
Also, some assays are known to be associated with very severe side effects while others
may cause little more than mild stomach discomfort. An optimized panel would weight
assays that predict serious side effects more strongly than those that predict minor
irritations.
5.4.4 Selecting an optimized panel
Quantifying the optimum level of hit-rate, assay-to-assay correlation, and assay-to-side-
effect correlation is challenging. It becomes particularly difficult when attempting to
28 Andreas Bender, et. al. Prediction of Adverse Drug Reactions and Off-target effects from chemical
structure based on Pharmacology Data.
combine the three parameters together because it is unclear how heavily various
components of the analysis should be weighted. A detailed analysis of this problem was
determined to be outside the scope of this project, however, a simplified analysis was
used as a first attempt to create a reduced primary panel of assays.
The simplified analysis took the form of three screens used in an iterative process. First
we filtered out assays with very low hit rates; second we looked at the receptor families
with multiple, well-correlated assays and removed the assays with the lowest hit rates and
least importance for safety; third we reviewed the entire list and removed those assays
identified in the literature as having low predictive value or predicted only minor side
effects. This analysis was performed by the pharmacology lab heads based on their
decades of experience in the field.
5.4.5 Split Panel Results
After the analysis of the existing assays, Preclinical Profiling at NIBR decided to create
two different Safety Pharmacology Panels. The primary panel, consisting of 40 assays,
will be used on all compounds submitted for Safety Pharmacology testing. The secondary
panel of 30 assays will be run upon request and at certain major decision points in
discovery process. The remaining 10 assays were dropped entirely from the in-house
panel.
The new process was reviewed and implemented and should result in materials cost
savings of $500,000 per year on an ongoing basis. In addition, as part of this change the
process time for the primary panel will be reduced by five days. With the panel split in
two pieces and with the reduced overall workload, the department is able to finish the
primary panel and report results in a single week instead of two weeks.
6 Safety Pharmacology Operational Improvements
6.1 Improvement Options
In our assessment of Safety Pharmacology Operations we identified many change
proposals to study. This section will describe three key changes in detail. They include
the following: changing the assay run frequency, changing the assay location, and
outsourcing portions of the assay.
6.1.1 Assay Run Frequency
The Safety Pharmacology Panel is processed as a batch in order to simplify the process of
creating the plates needed to perform the assay. As mentioned previously, increasing the
run frequency would significantly reduce both the queue time and process time for
incoming compounds. Discussions with the Safety Pharmacology department revealed
that a weekly assay schedule is feasible, though it would increase the labor requirements
due to the large setup times required to perform the assay. Other schedules of less than
one week or between one and two weeks were deemed either beyond the equipment
capability or unwieldy for the operators. This left two primary options for consideration,
the existing biweekly schedule or a weekly schedule.
In addition, we also proposed a hybrid schedule in response to the Split Panel described
previously. In this scenario the assay would still be performed on a biweekly schedule,
but the primary assay would be completed by the end of the first week. This reduces
cycle time by five days but does not provide a queue time reduction. This scenario
provides more modest cycle-time benefits but does so with little change in the amount of
labor required.
6.1.2 Assay Location
The assays in the Safety Pharmacology department are either performed at the Basel site
or at the Cambridge site, but not both. When a compound destined for Safety
Pharmacology arrives for processing at CMU it must be split into two solutions; one for
the local site and the other for the remote site. Cambridge only performs SPA assays
while Basel performs both Filtration and SPA assays. About 60% of the assays are
performed in Basel with the remainder in Cambridge.
Considering potential alternatives to this structure it is obvious that we could consolidate
all activities to a single site in either Basel or Cambridge, or expand each site so that it
could process the entire assay panel. A single site would have lower capital and labor
requirements, and two independent sites would have faster cycle times by avoiding
shipments. The current structure gains neither benefit. It requires all the overhead of two
sites, but gains none of the cycle time benefits because all compounds must be shipped
and processed at both sites.
6.1.3 Outsourcing the Secondary Panel
The split panel described above makes outsourcing an interesting alternative. Our
customer surveys indicate the requests for the secondary panel are likely to be less than
20% of total requests. Given this information it may be more cost effective to have a third
party perform these low-volume assays in the panel. The decrease in materials costs and
increase in capacity may be more valuable than the outsourcing fees.
Several external vendors already perform assays for NIBR and are capable of performing
all of the assays currently specified in the secondary panel. They typically guarantee
results within two weeks of receipt of the samples.
6.2 Evaluating the Options
In order to choose the combination of options that is best for the company, it is necessary
to understand the impact of each combination on the following criteria:
* Materials Costs
* Labor Costs
* Capital Costs
* Cycle Time
* Intangible factors
The following sections will describe how each of the these elements were modeled and
then how the results of those models were synthesized to gain a more complete
understanding of total impact of each permutation of the three changes identified earlier.
6.3 Materials Costs
Materials costs were estimated using a cost model created in Excel. The estimates were
made taking a top down approach starting with the overall materials usage of the entire
department. Based upon past expenditures and the volume of requests it was trivial to
calculate the average materials usage per assay by the department. We then adjusted this
amount for various internal factors such as expenditure on exploratory projects and other
non-assay related expenses. If we assume that all assays cost approximately the same
amount of money, we can readily calculate the overall materials costs for performing an
assay at a given rate of demand.
However, to determine the impact of changes in schedule, outsourcing, and location we
need to adjust the assay materials cost appropriately. A key parameter in this analysis is
the amount of material that is required for setup, regardless of the number of compounds
analyzed. This primary source of material waste is dead volume in the vials and
microplates. This is liquid required to wet the tube or vial that cannot be extracted by the
pipettes when transferring liquid from one tube to another. This amount was estimated at
20% by the department.
With this information it is relatively simple to estimate materials costs based on assay run
frequency, location, and outsourcing. An example is shown in Appendix 1.
This analysis ignores inventory carrying costs. Since each of these change options should
reduce inventories, this will cause a slight bias towards underestimating total savings.
The model also makes the aggressive assumption that the average cost of all assays
within the Safety Pharmacology Panel are equal. If the actual average cost of assays in
the secondary panel is significantly different from the average cost of assays in the
primary panel this could cause significant errors in the estimates. However, since the
number of assays in each group is relatively large, any specific effects from differences in
assay costs are averaged over many assays and are unlikely to cause large discrepancies
in our estimates. Also, the overall ratio of more expensive filtration assays to less
expensive SPA assays is roughly constant, so effects from changes in the assay mix are
unlikely to be significant.
6.4 Labor Requirements and Costs
In order to understand the impact of operational changes on labor requirements, a basic
labor model was created. The model assumes that labor can be divided into three types:
Setup time, run time, and site support. Setup time is the time required to prepare reagents
and equipment prior to the start of an experiment. It is modulated by the number and type
of assays that need to be performed, not by the number of compounds in a particular run.
Run time is the amount of time that the associate spends attending equipment and plates
during a particular experimental run and analyzing data for each compound. Run time is
primarily affected by the number of compounds or plates in an experiment. Site support
time is the time spent on inventory ordering, lab maintenance, and other activities that is
not dependent on the number of assays or the number of compounds being tested.
There are two types of assays in the Safety Pharmacology Panel: Scintillation Proximity
Assays (SPA) and filtration-binding assays. In the model, each assay type is assigned a
fraction that represents how much of the total time required to perform the assay is setup
time versus run time. For SPA assays we used a value of 80% and for Filtration assays a
value of 65%. We also chose a value for the number of assays of each type that one
person could successfully complete in one week's time. This number assumes that the
associate has a multitude of other tasks to complete such as assay development,
supporting project teams, and other activities that would keep him or her away from the
lab. The numbers we chose were 4 filtration assays and 8 SPA assays at a base level of
1800 compounds per year. We also assigned a value to site support activities of 0.5 FTE
(Full-time equivalents). Given these assumptions, we can find the total labor
requirements for any given number of assays per week and number of compounds per
assay. This model allows us to evaluate the impact of changes in the run frequency, assay
location, and outsourcing on the labor requirements.
NF = Number of Filtration Assays per week
N s  = Number of SPA Assays per week
Nsite = Number of Sites
SF = Setup Fraction Filtration
Ss  = Setup Fraction SPA
LF = Filtration Assays per week per unit of labor
Ls  = SPA Assays per week per unit of labor
Lsile = Site Support Labor
D = Demand in compounds per year
DB = Base Level of Demand
Labor= N SF+(1-S.). 1+1+ Ss +(1-Ss). 1+ +Nsie *Lte
L,[Fy D ) LS Dst
6.4.1 Validating the model
This model does not take a detailed bottom-up approach in determining labor
requirements, so it is difficult to measure the actual labor requirements directly versus
those predicted by the model. However, historical data exists allowing comparisons
between past scenarios and the model's predictions for those scenarios. Table 4 below
shows the model predictions versus actual amounts for three distinct historical periods.
This analysis assumes that headcount was not over or under-utilized during this period,
and that no significant changes in labor productivity occurred.
Scenario Prediction Error
A -4.2%
B -10%
C +8%
Average 7.4%
Table 4 - Labor Model Error
As we can see the model performed relatively well against historical data giving us
confidence that the predictions made by the model will be reasonably accurate.
6.4.2 Observations from the model
Using the model it becomes clear that the total demand has a relatively small impact on
the labor requirements. Increasing the number of compounds by 100% only causes a 20%
increase in labor. This is not surprising given that the setup fractions are very high. This
also has implications for running all assays at both sites. Since most of the work occurs in
setting up the assay, setting up all of the assays at both sites and running half the
compounds will require almost double the work of just running all assays at a single site.
The same can be said for running the assays weekly instead of biweekly. Doubling the
number of setups will come close to doubling the amount of labor required.
6.4.3 Model Considerations and Assumptions
This simplified model makes several strong assumptions that limit the utility of the
model.
Productivity is Constant
The model assumes that labor productivity is constant. This assumption is likely
to become inaccurate as the organization acquires additional capital and changes assay
procedures. However, the model can easily be adjusted with new setup fractions and
labor constants that reflect the impact of the operational changes.
Productivity is Equal
The capital equipment, procedures, and personnel in Basel and Cambridge are not
the same. This will likely cause differences in the productivity of each site. These
differences are not accounted for in the model.
All Assays are Equal
The model assumes that the amount of work required to perform a particular
assay type is always the same. This assumption is not strictly true. In reality there are
multiple sub-types of filtration and SPA assays that have slightly different procedures. In
addition, certain assays are less likely to yield good results, causing different rework
rates. These considerations are also missing from the model.
Labor Changes Linearly
The model adjusts the amount of labor required linearly based on the number of
assays and the number of compounds. This is a relatively good assumption for small
changes, but as the changes from the baseline become large it is likely that the
relationship will cease to be linear.
Though the model has significant limitations, it functions well for its designed use - to
provide a rough estimate of how labor requirements will change as we change the
operational parameters of the assay.
6.4.4 Modeling labor costs
When comparing investment proposals Novartis uses a standard value for the cost of one
full-time worker, also known in the company as an FTE (Full-time equivalent). For the
purposes of discussion, assume this value is $250,000. This number is determined by
adding up all of the costs allocated to a department and then dividing by the number of
people in the department. These costs include everything from salaries to building rent to
IT support to direct materials purchased.
However, when evaluating the impact of changes to the operational structure, this FTE
cost value can be misleading. For example, if a department is contemplating a change that
would save $250,000 in materials and free up one FTE they might compute their total
savings as $500,000. However, since the FTE component already includes materials cost,
they are double-counting some of the materials savings. The actual savings may be only
$450,000. Labor costs are convoluted with all other costs, leading to some confusion
when attempting to estimate the real impact of change proposals.
In the cost model that we created to evaluate our change proposals we separated costs
that were directly related to headcount from costs that are related to other factors. We
performed this separation for each individual cost category used by the department. We
assumed that infrastructure, IT, salaries, benefits, and travel were headcount related.
However, depreciation and materials costs were independent of the number of employees
in the department. This allowed us to determine a new average value of the cost of one
FTE in both Basel and Cambridge that is not convoluted with other factors.
By combining this updated cost information with the labor model discussed below, we
were able to e:stimate the true cost or savings associated with changes in labor
requirements with greater accuracy. If we had used the standard value for labor costs, our
estimates would have double-counted savings resulting in estimation errors of up to 25%.
6.5 Capital Costs
Some of the change options being considered require capital cost investments.
Specifically, performing all assays in both locations would require Cambridge to
purchase additional capital equipment for performing filtration assays that it does not
currently have the capability to do. The other major potential source of capital investment
is the software and hardware to enable individual compound ordering. To estimate these
costs we contacted appropriate hardware and software vendors, described our
requirements, and received estimates for the capital cost outlay that would be required.
These capital costs were incorporated into the NPV calculation as a cash outflow in year
zero with cash inflows in the form of tax benefits from depreciation allowances in years
1-5. We assumed a straight-line depreciation over 5 years with a 30% tax rate.
One capital-related item missing from the model is the impact of site consolidation on
capital costs. Currently the model does not allocate any ongoing savings or costs related
to the disposition of equipment that will be made redundant by the consolidation
activities. This will likely understate the potential savings of consolidating to a single
site. In addition, future expenses and upgrades will now only need to be made at a single
site, which will likely provide more ongoing savings that are not accounted for in the
model.
6.6 Cycle Time
In order to examine the impact of changes to the process I created a simple simulation of
the Safety Pharmacology process using the parameters shown above in the process flow
diagram. The model makes another key assumption, that capacity is infinite. This
assumption was chosen because recent modifications to the Pharmacology area have
increased the capacity of a single run so that the likelihood of submissions exceeding
capacity in any given week is less than 3%.
Also, the model does not use a strictly normal distribution for calculating turnaround
times. Since the area operates on a daily schedule, if an activity is accomplished a few
hours early it has no impact as long as the material is ready for the processing step that
will take place in the following day. Because of this I used discrete time periods with a
minimum unit of 1 day. For example, when modeling shipping I used a discrete custom
distribution in which there is a 20% chance of waiting for 1 day, a 20% chance of waiting
for 2 days, a 20% chance of waiting for 3 days, etc. Similarly, for compound
management I assumed that 50% of the time the compounds will be completed in one
day, but 50% of the time it will take two days. Additional details can be seen in Appendix
2 below.
When the simulation is complete it allows us to estimate average, median and 9 0 th
percentile cycle times for multiple scenarios. In particular I modeled the current situation
in which the assay package is run once every two weeks, the future planned situation in
which the assay is run every two weeks, but the data is reported at the end of the first
week, and the potential option of running the entire assay every week. The results are
shown in the table below.
Scenario Average Median 90th Percentile % < 20 days
Biweekly Runs 21.5 21 26 40%
Biweekly, data in first week 16.5 16 21 87%
Weekly Runs 14 14 17 100%
Table 5 - Cycle Time Model Results
6.7 Intangibles
Each option carries with it not only significant labor, material, and capital changes but
also other impacts that are not directly accounted for in the model. Some of the
considerations that fall outside the model are described below for each of the major
change options.
Assay Run Frequency
The primary intangible effect in changing the assay run frequency is the impact on the
personnel. The associates fear that increasing the run frequency will force them to spend
all of their time simply running the assay and leave them little time left for their other
duties. The labor model projects significantly higher labor demands for higher run
frequencies, so this concern can be alleviated if additional resources are provided as
suggested by the model.
Outsourcing
One significant concern with outsourcing is data quality and consistency. Due to
differences in assay formats, IC 50's from vendors will likely be based on a smaller
number of data points, slightly reducing the accuracy of the IC50 data and making direct
comparisons to previous internal data a bit more difficult. Another concern is the impact
of changes in demand. In a typical contract NIBR must guarantee a certain volume of
orders to obtain preferential pricing. Should NIBR's needs be less than forecast, they will
be forced to pay extra costs. Outsourcing in this case takes what are now variable costs
and transforms them into fixed costs, increasing the sensitivity to demand shortfalls. In
the case of excess demand, NIBR will be forced to either exceed its budget or ration
assay capacity.
Assay Location
The location chosen to perform the assays is potentially disruptive to the personnel
affected. Certain employees would be forced to either move or find new jobs within the
company. Also, there are some concerns that consolidating to a single site reduces the
accessibility of safety pharmacology expertise in the company. Chemists at the site that is
closed would not have local access to subject matter experts and would have to rely on a
remote site when they have questions. Further, consolidating to a single site could reduce
the amount of time available for development and optimization activities.
6.8 Synthesizing the Model Output
The purpose of creating basic models for materials, labor, capital, and cycle time was to
synthesize a complete picture of how different operations changes would affect the total
costs and cycle time of the process. As mentioned previously we decided to focus on
three change options that were closely tied together: the assay run frequency, the assay
location, and whether or not to outsource the secondary panel. With three variables, two
having two levels and one having four levels, the total possible number of combinations
is sixteen. We also have four different outputs to measure: materials, labor, capital, and
cycle time. To simplify the output we compressed materials, labor and capital into a
single quantity of dollars and calculated the 5-year Net-Present Value or NPV of
choosing that option compared to doing nothing. This leaves us with a more manageable
two outputs of NPV and cycle time. When we plot each of the possible options on those
two measures we create the following chart below.
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Figure 25 - P5 Options, NPV and Cycle Time
This view allows us to compare the NPV and cycle time of all sixteen options in a single
view. Certain options maximize NPV at a given turnaround time, these options could be
said to lay on the efficient frontier. We can also see the tradeoff between NPV and cycle
time. Depending on the relative importance of cycle time and NPV, we can choose to
operate at any point on that efficient frontier.
It is also helpful to have some insight into the source of the difference in NPV. In order to
separate the benefit from a direct cost standpoint vis-a-vis a labor standpoint we created
the following bubble chart that shows labor impact on the y-axis, NPV not including
labor on the X-axis, with the size of the bubble showing the average turnaround time.
This is shown in the figure below.
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Figure 26 - Options by NPV, FTE's & Cycle Time
This type of analysis is important to consider because labor savings in the model are
unlikely to be realized by reducing headcount. Instead, the "savings" are more likely to
be realized in the form of additional projects that can now be accomplished by the
department. How the company views the benefit of this additional employee bandwidth
may cause them to place a different value on these labor savings.
6.9 Recommendations
Given the results of the analysis above, two options present the best overall performance.
The first is consolidating operations to a single site and running the assay biweekly
without outsourcing the secondary panel. The second option is to consolidate operations,
outsource the secondary panel, and run the primary panel weekly. The first option
provides a 5-year NPV that is over $1 million higher than option 2, however it provides a
90t percentile cycle time of nearly three weeks. Option two is more expensive, but
reduces the 90 th percentile cycle time to less than 12 business days.
In every case, consolidating operations to a single site was more cost-effective than
maintaining two sites each performing part of the assay. We also determined that in
general it is preferable to choose to outsource when running on a weekly schedule in
order to avoid large increases in the labor requirements. When choosing a biweekly
schedule, however, the savings due to outsourcing are not significant.
P5 Options by NPV, FTEs & Turnaround Time
(Area of Circle proportional to turnaround time in business days)
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7 Long Term Strategy
The analysis presented in sections five and six needs to be evaluated within the context of
the strategy of the organization. Many external firms specialize in doing the type of
compound profiling that Novartis is doing in house. Novartis uses some of these firms to
supplement their internal profiling activities. A critical question for Novartis is, "What is
the strategy of their internal profiling group"? The internal organization has two primary
options, they can either choose to be the low-cost provider or choose to offer a higher
quality product than their external competitors are capable of.29
The source of a sustainable, long-term competitive advantage can be derived from a
firm's unique capabilities or position.30 As an internal organization, PCP has a unique
position that comes with significant advantages and disadvantages. PCP has a built-in
advantage in turnaround time and in potential for collaboration with internal colleagues.
However, the internal group also has a distinct disadvantage due to their high fixed costs
associated with operating in a high-cost area like Cambridge.
7.1 Two Strategic Options
The PCP group has two primary choices when evaluating the structure of the product
they offer to their internal customers. They can either choose to offer a custom structure
or a generic structure. The custom option is essentially the individual ordering system
described previously. In this scenario, PCP allows the customers to pick which assays to
perform on which compounds without any restriction. Chemists would be free to choose
the assays that best suit their needs. This option assumes that each discovery program has
different needs and that those needs cannot be effectively met by a standardized
screening mechanism
The generic structure option assumes the opposite, that most discovery programs are
essentially the same and that a well designed package of standard screens will satisfy all
of the critical demands of the company. In this scenario, ordering is greatly simplified.
PCP would only offer a limited menu of assay packages designed to capture the most
common problems that development programs face.
PCP also faces a choice in the type of product to offer to their customers. Currently
profiling is a data provider. Customers ask for the solubility of several compounds and in
return they receive several numbers. However, PCP also has the ability to provide
analysis, rather than data alone. The Cambridge organization has been experimenting
with placing profiling associates on the drug development teams. These individuals are
the primary contact for answering profiling related questions. Since the associates are
scientists in their own right with bachelors and masters degrees they are capable of
providing much more. PCP could provide analysis of multiple compounds in multiple
29 Source: Saloner, Garth, et al. Strategic Management. 200130 Source: Saloner, Garth, et al. Strategic Management. 2001
assays to create an integrated risk assessment and suggestions to the drug discovery
program. They could be an integral part of helping the chemists to select the appropriate
assays for the appropriate compounds and in helping them to understand the meaning of
all of the data as it is provided.
7.2 Evaluating the Options
This leaves PCP with a matrix of options. They can choose to provide a general or a
custom structure with either data or analysis as their primary product. The four possible
options are shown in the table below.
Figure 27 - PCP Strategic Options
As shown on the figure, the upper-right quadrant and the lower-left quadrant both have
problems with strategic fit. If PCP offered detailed analysis with a general structure, they
are quite limited in how they can help the development teams. They may be able to help
with the meaning of results, but when it comes to next steps and follow up assays to
perform, their expertise is wasted because they can only recommend one of the obvious
choices on the menu.
If a custom structure is paired with providing only data, the project teams are required to
have the expertise to not only interpret that data, but also make decisions on future
profiling direction based on the data they received. In addition, every development team
at Novartis will need a deep level of expertise in profiling for the company to take
advantage of the investment in a custom profiling structure.
Clearly, the best options lie in either providing a custom structure with analysis or a
general structure with just the data. Currently, PCP sits in the middle. They offer some
assays individually, while others are in packages. They offer just data to most customers,
but are starting to offer more analysis to others. To be successful in the long run, the
organization needs to commit to a strategy and embrace it wholeheartedly to gain all of
the potential advantages. To embrace either option would require significant changes in
their organization and their operations.
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If PCP chose to offer the general structure and provide only the data, they would be in a
position to offer low costs. However, it is questionable how long that advantage would
last since they are confined to operating in a high cost location. Over time it is likely that
external vendors, operating in low cost areas, could replicate the capabilities of the
Novartis Profiling group and offer those services at a lower cost. Novartis already
compares its internal assay cost with the cost of outsourcing. For certain assays, external
vendors already offer prices that are slightly below the internal cost.
8 Organizational Considerations
8.1 Strategic Design Factors
8.1.1 PCP Organizational Structure
The PCP organization is divided along functional lines. There are separate groups for
each major assay class such as absorption, cellular toxicity, and safety pharmacology.
Each group is lead by a lab head who has 1-3 direct reports. Lab Heads are almost always
Ph.D.'s. Each associate who works for the lab head is typically responsible for a specific
assay and often works individually rather than as part of a team. The Associates typically
have Bachelors or Masters degrees in a science major like biology or chemistry. Though
some associates know how to perform multiple assays, most are only comfortable with
their own primary assay.
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Figure 28 - US PCP Organizational Chart
The profiling group in Cambridge has a companion group in Basel that performs many of
the same functions. Some assays are performed at both locations while others are
performed only in Cambridge. At a global level the head of profiling for both Basel and
Cambridge report to the local head of Discovery Technologies (DT). The local heads of
DT then report in to global head of DT. The US head of DT is also designated as the
Global Head of Profiling, so the Basel head of profiling has a dotted-line reporting
relationship to the US head of DT.
6 w •I
I I I
I I I
I !1 I
Figure 29 - Global Reporting Structure for Profiling
8.1.2 Implications of the Organizational Structure:
The Basel and Cambridge organizations do not share a common direct manager until one
step below the President of NIBR. This makes synchronization and agreement between
Basel and Cambridge more difficult than it might be if all of Profiling reported to a single
manager who could set direction for the entire organization. There are established lines of
communication between the lab heads at each site which help with coordination, but
these connections do not extend down to the level of the associates. Also, since the
customers of PCP services are in a completely separate organization, evaluating the needs
of the customers is more difficult and can be a point of disagreement.
8.2 Organizational Recommendations
8.2.1 Reorganize Departmental Structure
In the current organizational structure, associates are under a glass ceiling. Since lab
heads are culturally required to have PhD's to confer necessary legitimacy, associates
have very few options in establishing a career path within the company. Also, the
structure of the organization focuses on developing assays in each functional department
rather than focusing on daily operations. Further, associates are required to perform a lot
of manual, repetitive tasks that are required to keep running the assays. These problems
are difficult to address without redefining the structure and relationships within the
department. A proposed alternative structure is shown below in Figure 30.
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Figure 30 - Proposed Organizational Structure32
This structure creates several new roles. At the bottom of the organization it creates a
layer of technicians. These technicians would be responsible for the daily manual tasks
associated with handling samples, setting up the assays, and performing the assays
themselves. Supervising these technicians would be an Operations Manager whose
primary task is making sure the daily operations run smoothly. This manager would track
cycle time and cost performance and ensure that materials flows through the group
smoothly.
Associates would work closely with the technicians and would retain responsibility for
assay procedures and quality. In effect they would serve an engineering function and
would be freed from the repetitive tasks of physically performing their assay. The
associates would report to Group Leaders whose primary responsibility would be
management of the associates. Each Group Leader would have six or more associates
instead of the 1-3 that each Lab Head is responsible for today. Group Leaders would also
do project management tasks and coordinate with the Operations Manager to ensure
Operations received the support it requires.
Research Scientists would focus on assay and technology development activities. They
would be the technical experts in the department and would be assisted by the associates
on certain projects, especially as assays were getting ready to transition to full
production.
This new structure provides an appropriate career path for all members of the
organization. They can progress on either an individual contributor or management career
path as shown in Figure 31.
32 Developed in association with Rebecca Roberts, LFM Class of 2007
Individual Contributor
Career Path
Figure 31 - Career Paths in New Organization33
Associates in the new organization have more freedom to do interesting work,
Operational focus is built into the organization with the Operations Manager role, and
researchers can devote their full time to research instead of being saddled with
management and daily operational activities.
8.2.2 Change Management Reporting Structure
The split management structure in PCP can lead to difficulties in creating a shared vision
and challenges in getting the two sites to work together as an integrated team. A more
direct reporting relationship would simplify the process of creating a common strategy,
common metrics, and common goals. The head of profiling at each site should have a
solid-line reporting relationship to a single individual.
8.2.3 Use Balanced Scorecards as Management Tool
NIBR uses a Balanced Scorecard methodology to do its individual performance
reviews. 34 However, these Balanced Scorecards are not typically used in the normal
course of business in the Discovery Technologies group. In group meetings it is rare to
see any mention of specific group goals and current performance relative to those goals.
Since the group has already invested in the creation of Balanced Scorecards, they should
use them more aggressively to help manage their performance on an ongoing basis.
33 Developed by Rebecca Roberts, LFM Class of 2007
Source: Kaplan, Robert S. and David P. Norton, "The Balanced Scorecard: Translating Strategy into
Action."
9 Conclusions
Based upon the analysis presented earlier the NIBR Profiling group should adopt the
following recommendations:
* Create a split panel structure for Safety Pharmacology (complete)
* Consolidate all Safety Pharmacology activity to a single site
* Outsource the secondary panel when moving to weekly run schedule
* Adopt a custom/analysis strategy to maximize long-term value
* Update the organizational structure to improve operational focus
This package of changes will enhance the cost-effectiveness of the PCP organization.
Resources will be better allocated, cycle times will be reduced, and costs will decrease.
Over the long term, the strategic and organizational changes will enable PCP to continue
to improve and be competitive.
In addition to some specific recommendations, throughout this project the following
principles emerged that are generally applicable.
The Importance of Analyzing the Entire Process Flow
One the critical failings in the Profiling department was considering only the activities
and impact of changes within the department itself. For example, when measuring cycle
time, internal metrics indicated performance was good, but looking at the entire process
flow showed cycle time performance was extremely poor. The decisions of any once
piece of the process inevitably affect the steps before and after. Metrics and change
proposals need to include the impact on the entire system rather than just the local
department.
Tools of Operational Analysis are Broadly Applicable
The types of tools used in this analysis such as process flow mapping, cost modeling,
monte-carlo simulations, etc. are common practice in manufacturing companies. This
thesis as well as previous Leaders for Manufacturing Theses35,36 have shown that these
tools are broadly applicable, even in unlikely areas such as early-stage drug discovery
research. Any activity that is repeated or follows a process can be analyzed and improved
using these types of tools.
Combining simple models together can provide an integrated view of interacting change
proposals
Multiple change proposals in a single department must be evaluated in concert to avoid
selecting a sub-optimal combination of options. In these situations, simple models can be
combined together to give an understanding of how the proposals interact along multiple
35Source: Vokoun, Matthew, Operations Capability Improvement of a Molecular Biology Laboratory in a
High Throughput Genome Sequencing Center. 2005.36 Source: Penake, David A. Enabling Sample Tracking in and Reducing Variability in DNA Library
Construction. 2006.
dimensions. Based upon this type of analysis, options that maximize two or more desired
outputs can be identified and implemented.
Internal service organizations must develop a long-term strategy to add value
Captive internal service organizations have significant positional advantages and
disadvantages with respect to third party vendors. In order to survive they must identify
and implement a strategic vision that will exploit those advantages and provide superior
long-term performance. Without a coherent, long-term strategy that takes advantage of
internal relationships and interests, these organizations will be replaced through
outsourcing.
10 Future Opportunities
In addition to the recommendations in this thesis, there are many other opportunities for
improvement in the Profiling organization. Some of these include redesigning for
continuous flow, implementing ideas from lean manufacturing, and using statistical
process control to improve assay quality.
Redesign for Continous Flow
The increasing miniaturization in the pharmaceutical industry has the effect of driving
ever-increasing batch sizes in PCP. The smallest element in an experiment is the
microplate. These plates have become more and more dense moving from 96-well to 384-
well to 1536-well plates. The automation systems are designed to handle a full plate at a
time. Running a partially filled plate typically wastes reagents. This system works
relatively well for high-throughput screening in which the compounds to be tested
already exist in inventory in a library. In PCP, the compounds are novel and are produced
in as a steady stream. Creating full plates requires ever larger batches of compounds and
hence ever increasing queue-times. The automation systems for Profiling could be
completely redesigned and reconceived to enable samples to be processed one at a time
or just a few at time. The actual process time for any assay is often 1-2 days. With a
continuous flow system queue time could approach zero and overall cycle time for any
assay could be reduced to just a few days, a dramatic improvement from the 1-4 weeks
that is common today.
Implement Lean Laboratory Practices
The laboratories at NIBR could benefit from employing the basic concepts of Lean
Manufacturing. Successful implementation of these principles has been done previously
in a similar environment at the Broad Institute.37 At NIBR, procedures at lack
standardization and documentation, labs are typically messy and full of equipment,
consumable inventory is piled up all over, and metrics are not easily accessible. The basic
techniques of 5S, standardized work, kanbans, and continuous improvement could
significantly improve performance in the area. 38
37 Source: Vokoun, Matthew, "Operations Capability Improvement of a Molecular Biology Laboratory in a
High Throughput Genome Sequencing Center."
38 Source: Dennis, Pascal. Lean Production Simplified. 2002
Implement Statistical Process Control
Currently there are no metrics to track the performance of key assay parameters on a run
to run basis. Many of the assays have built in quality checks that are used as lower limits
to determine if an assay must be repeated. However these quality indicators are not
systematically tracked or used over time. Employing control charts and statistical process
control techniques could significantly increase quality and reduce the occurrence of
rework. Assays with marginal performance could be easily identified and improved by
optimizing the assay run protocols. Problems with reagents or equipment could be more
quickly and more easily identified. Creating a system and a culture of quality
performance tracking would be challenging but could yield significant long-term results.
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12 Appendix A- Materials Cost Modeling
This is an example of the cost modeling for the Safety Pharmacology options analysis
using fictional numbers. The first table shows the assumptions made and the second how
the calculations were performed.
Value Comments
Cambridge FTE cost/yr
Basel FTE cost/yr
Base Materials Cost
R&D materials cost percentage
Dead Volume
$120,000
$100,000
$1,000,000
10%
20%
Compound demand/yr for secondary assay 500
Outsourcing cost/well $25
% Hits in outsourced assays 20%
Outsourcing cost/cmpd/assay $80.00
Capital Expndidre
Materials Savings due to Individual Ordering
Capital for Ind. Ordering on 2 sites
Capital for Ind. Ordering on 1 site
Capital for All assays at both sites
Tax Rate
Non-production costs
= cost/well*(2) + (hit%) *
(cost/well)*6
(assumes single
concentration in duplicate
with 6pt IC50 follow-up)
25%
$1,000,000
$500,000
$250,000
30%
Equipment Lifetime (for dep. Schedule) 5
Cost of Capital 15%
Table 6 - Assumptions used in Safety Pharmacology Cost Model
Value Comments
Individual Ordering
Primary Assays
Secondary Assays
Outsource Secondary?
Assay Frequency
Location
Capital Cost $
8 Outsourcing Cost
Base cost for primary
9 assays
Yes Choose Yes or No
40 Choose value
30 Choose Value
No Choose Yes or No
25 Choose 25 or 50 runs per year
Both Choose Both, All, Basel, Cambridge
1,000,000 estimate from assumptions
(# of Secondary Assays)*Outsourcing
cost/cmp/assay * demand for secondary
$0 assays
number of primary assays/Base # of assays *
$533,333 base materials cost
Assumptions
Item
~·~&m
.
Materials increase due to
10 run frequency
Savings from individual
ordering
Materials Cost Subtotal
Secondary Assay
13 Materials
14 Adjustment for # of sites
Materials Difference from
15 base
Net Ch
Expen
Basel
Cambi
Total L
Labor
Depre
(Straig
Other
5-Year
Dead volume fraction*(base cost for primary
assays)*(new runs/yr - old runs/yr) / (old
$0 runs/yr)
(Ind. Ordering savings rate)*(1-dead volume
($106,667) fraction)*(materials cost subtotal)
$426,667 sum of previous 3 items
if outsource=no then (secondary cmpds/Base
demand)*(Cost subtotal for Base demand
cmpds)*
(number secondary assays/number of primary
assays)*(1 -dead volume fraction)+
dead volume fraction*(number secondary
assays/number primary assays)*base
$151,111 materials cost for primary assays
if Location=all then (dead volume
fraction)*base cost for primary assays +
$0 materials increase due to run frequency
Base Materials Cost - Materials Cost subtotal -
Secondary Assay Materials - Adjustment for #($422,222) of sites
iange in Cash Sum of Materials difference from base and
diture/yr ($422,222) Outsourcing Cost
FTE Impact -1 estimate of labor changes from labor model
ridge FTE Impact -0.5 estimate of labor changes from labor model
abor Change -1.5 Sum of previous 2 items
Basel FTE Impact* Basel FTE cost +
Cost ($160,000) Cambridge FTE Impact * Cambridge FTE cost
ciation Tax Benefit tax rate * (capital investment/ years
ht line) ($60,000) depreciated)
Annual Costs any other manual adjustments
r NPV w/o Labor $616,484 5-year NPV not including labor cost savings
I 5-year NPV
Table 7 - Calculations from Safety Pharmacology Cost Model
13 Appendix B - Cycle Time Modeling
Following is an example of the type of cycle time assumptions made in the cycle time
model. Also shown is an example output of the expected distribution of the cycle time of
compounds going through the system.
Time
(business
Step days) Probability
0 20%1 - Compound
Submission 1 70%
2 10%
2 - CMU 1 50%
Processing 2 50%
3 - Shipping
Required?
4 - Shipping
Delay
5 - Shipping
Time
6 - Assay
Queue
7 - Assay
Processing
0
1
1
2
3
4
5
1
2
3
1
2
3
4
5
6
7
8
9
10
8
9
10
11
12
50%
50%
20%
20%
20%
20%
20%
20%
60%
20%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
5%
10%
70%
10%
5%
Total Time = Step 1 + Step 2 +
Step 3 * (Step 4 + Step 5) +
Step 6 + Step 7
Table 8 - Sample Assumptions for Cycle Time Model
Table 9 - Output of Cycle Time Simulation
